- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers — Active Not Recruiting • Phase III • Oncology • NCT05152147.
- Testing whether zanidatamab combined with chemotherapy (with or without an immunotherapy drug) works better than standard trastuzumab treatment in advanced stomach and gullet cancers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic). Conditions: Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma Interventions: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil Lead Sponsor: Jazz Pharmaceuticals Planned Enrollment: 920…